Table 4.
Changes in glycemic control, quality of life and disease burden among persons who continued FSL-FGM for at least 2 years and persons who had stopped FSL-FGM before the 2-year follow-up period was completed
| Baseline (A) | 1 year (B) | 2 years (C) | C vs A | C vs B | Overall difference between groups | ||||||
| Continued FSL-FGM | Stopped FSL-FGM | Continued FSL-FGM | Stopped FSL-FGM | Continued FSL-FGM | Stopped FSL-FGM | Continued FSL-FGM | Stopped FSL-FGM | Continued FSL-FGM | Stopped FSL-FGM |
||
| Glycemia | |||||||||||
| HbA1c | 62.4 (60.8 to 64.0) | 59.0 (56.2 to 61.8) | 58.3 (56.8 to 59.7) | 56.4 (53.8 to 58.9) | 58.9 (57.2 to 60.6) | 56.7 (53.6 to 59.8) | 3.5 (−6.4 to −0.7) | −2.4 (−7.5 to 2.7) | 0.6 (−2.1 to 3.4) | 0.3 (−4.6 to 5.2) | 2.2 (−1.3 to 5.8) |
| n | 259 | 82 | 191 | 62 | 260 | 82 | |||||
| Hypoglycemic events | 61.8 (52.8 to 70.8) | 67.5 (51.1 to 83.9) | 60.3 (49.7 to 70.9) | 72.3 (52.4 to 92.2) | 51.3 (43.0 to 59.7) | 50.7 (35.0 to 66.4) | −10.5 (−25.4 to 4.5) | −16.8 (−44.5 to 10.9) | −9.0 (−25.5 to 7.5) | −21.6 (−52.5 to 9.4) | 0.6 (−17.2 to 18.4) |
| n | 250 | 75 | 242 | 69 | 229 | 65 | |||||
| Quality of life | |||||||||||
| EQ-VAS | 70.9 (69.5 to 74.2) | 67.7 (63.6 to 71.9) | 73.8 (71.2 to 76.4) | 69.6 (64.9 to 74.2) | 74.8 (71.9 to 77.6) | 74.8 (71.9 to 77.6) | 2.9 (−1.7 to 7.4) | 5.3 (−2.8 to 13.4) | 0.9 (−3.8 to 5.7) | 3.5 (−5.0 to 12.0) | 1.7 (−4.2 to 7.6) |
| n | 260 | 82 | 260 | 82 | 265 | 80 | |||||
| EQ-5D-3L Dutch tariff | 0.85 (0.83 to 0.87) | 0.84 (0.80 to 0.88) | 0.87 (0.85 to 0.90) | 0.84 (0.80 to 0.88) | 0.88 (0.85 to 0.90) | 0.81 (0.77 to 0.85) | 0.02 (−0.02 to 0.06) | −0.03 (−0.10 to 0.04) | 0.002 (−0.04 to 0.04) | −0.03 (−0.1 to 0.04) | 0.07 (0.02 to 0.1) |
| n | 260 | 82 | 260 | 82 | 256 | 80 | |||||
| SF-12v2 PCS score | 37.6 (36.9 to 38.3) | 38.7 (37.5 to 40.0) | 47.4 (46.4 to 48.4) | 47.1 (45.3 to 48.8) | 47.2 (46.2 to 48.2) | 46.5 (44.8 to 48.3) | 9.6 (8.1 to 11.0) | 7.8 (5.2 to 11.5) | −0.2 (−1.9 to 1.5) | −0.5 (−3.5 to 2.5) | 0.7 (−1.4 to 2.7) |
| n | 260 | 82 | 260 | 82 | 260 | 82 | |||||
| SF-12v2 MCS score | 50.1 (48.8 to 51.3) | 47.6 (45.4 to 49.9) | 51.1 (50.0 to 52.1) | 47.8 (45.9 to 49.6) | 50.0 (48.9 to 51.1) | 45.0 (43.1 to 47.0) | −0.03 (−2.1 to 2.0) | −2.6 (−6.2 to 1.1) | −1.1 (−2.9 to 0.8) | −2.7 (−6.1 to 0.6) | 5.0 (2.7 to 7.3) |
| n | 260 | 82 | 254 | 79 | 254 | 79 | |||||
| Disease burden | |||||||||||
| Hospital admissions | 0.1 (0.07 to 0.2) | 0.1 (−0.04 to 0.2) | 0.1 (0.03 to 0.2) | 0.02 (−1.0 to 0.1) | 2.1 (−1.4 to 5.5) | 0.6 (−5.5 to 6.7) | 1.9 (−2.3 to 6.1) | 0.5 (−7.0 to 8.0) | 2.0 (−2.2 to 6.2) | 0.6 (−6.9 to 8.1) | 2.1 (−1.4 to 5.5) |
| n | 260 | 82 | 260 | 82 | 259 | 82 | |||||
| Lost working days | 4.9 (1.6 to 8.1) | 7.2 (1.4 to 13.0) | 2.2 (−0.7 to 5.0) | 8.0 (3.0 to 13.1) | 3.4 (−0.7 to 7.5) | 8.0 (3.0 to 13.1) | −1.5 (−7.9 to 4.9) | 0.9 (−10.5 to 12.2) | 1.2 (−4.9 to 7.3) | 0.01 (−10.8 to 10.8) | −4.6 (−13.0 to 3.7) |
| n | 260 | 82 | 260 | 82 | 257 | 82 | |||||
Data are presented as mean (difference) with 95% CI.
HbA1c concentrations are presented in mmol/mol.
EQ-5D-3L, three-level version of EuroQol 5-Dimension; EQ-VAS, EQ-Visual Analogue Scale; FSL-FGM, FreeStyle Libre flash glucose monitoring; HbA1c, hemoglobin A1c; MCS, Mental Component Summary; PCS, Physical Component Summary; SF-12v2, 12-Item Short Form Health Survey version 2.